Panacea Biotec Limited
PANACEABIO (NSE)

128.25

786.17
Proj. ROE (%)
-
Proj. P/E (x)
-
Proj EV / EBITDA (x)
-
Proj. P/BV (x)
-
Proj. Revenue ( Cr.)
-

Stock View

-
Share on
The average score for Panacea Biotec Limited stands at 6 against 4, three months back.

Panacea Biotec Limited is an India-based biotechnology company, which is engaged in research and development, manufacturing, sales, distribution and marketing of pharmaceuticals, vaccines and biosimilars business. The Company’s research areas include new chemical entities (NCE), new biological entities (NBE) novel drug delivery system (NDDS) based pharmaceutical formulations, novel peptides and human monoclonal antibodies and vaccine development. The Company’s product portfolio includes pain management, diabetes & cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, gastrointestinal care products and vaccines. The Company’s subsidiaries include Panacea Biotec Pharma Limited, Panacea Biotec (International) SA, PanEra Biotec Private Limited and Meyten Realtech Private Limited.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.

Technical Data
50 DMA()
145.53
100 DMA ()
166.38
200 DMA ()
196.03
52 Weeks Range
125.00
412.30
Street View :-
Bearish
Open ZERO Brokerage Demat Account
Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity